Aeglea BioTherapeutics (NASDAQ:AGLE) Receives New Coverage from Analysts at StockNews.com

Posted by Defense World Staff on Jun 6th, 2023

StockNews.com assumed coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a report issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Several other research analysts have also recently commented on AGLE. Lifesci Capital cut Aeglea BioTherapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 12th. Jonestrading reaffirmed a “hold” rating on shares of Aeglea BioTherapeutics in a research report on Wednesday, April 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Aeglea BioTherapeutics in a research report on Friday, March 3rd. Finally, Wells Fargo & Company cut Aeglea BioTherapeutics from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, April 12th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $1.88.

Aeglea BioTherapeutics Stock Performance

NASDAQ:AGLE opened at $0.12 on Tuesday. The company has a market cap of $7.98 million, a PE ratio of -0.15 and a beta of 1.74. Aeglea BioTherapeutics has a 52-week low of $0.11 and a 52-week high of $1.56. The stock has a 50-day simple moving average of $0.18 and a 200 day simple moving average of $0.39.

Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) last posted its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.17 million. Aeglea BioTherapeutics had a negative return on equity of 132.05% and a negative net margin of 6,678.20%. On average, research analysts predict that Aeglea BioTherapeutics will post -0.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aeglea BioTherapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC grew its position in Aeglea BioTherapeutics by 24.3% during the 4th quarter. Nantahala Capital Management LLC now owns 4,611,302 shares of the biotechnology company’s stock worth $2,075,000 after acquiring an additional 900,524 shares during the last quarter. Millennium Management LLC grew its position in Aeglea BioTherapeutics by 284.4% during the 4th quarter. Millennium Management LLC now owns 3,131,479 shares of the biotechnology company’s stock worth $1,409,000 after acquiring an additional 2,316,807 shares during the last quarter. Rock Springs Capital Management LP grew its position in Aeglea BioTherapeutics by 14.8% during the 1st quarter. Rock Springs Capital Management LP now owns 1,811,425 shares of the biotechnology company’s stock worth $4,166,000 after acquiring an additional 234,129 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Aeglea BioTherapeutics by 5.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,187,293 shares of the biotechnology company’s stock worth $600,000 after buying an additional 62,504 shares during the period. Finally, Pura Vida Investments LLC acquired a new position in Aeglea BioTherapeutics during the 4th quarter worth about $472,000. Institutional investors own 78.01% of the company’s stock.

Aeglea BioTherapeutics Company Profile

(Get Rating)

Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.